Evidence map›Paper›PMID 21613610›Full record

ArticleAmerican journal of physiology. Cell physiology2011

Intracellular angiotensin II activates rat myometrium.

Elena Deliu, Andrei A Tica, Dana Motoc, G Cristina Brailoiu, Eugen Brailoiu

Abstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Mechanistic study on the role of multi-pathway autophagy in ovarian aging: literature review.Apoptosis : an international journal on programmed cell death · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Luminal ANG II is internalized as a complex with ATAmerican journal of physiology. Renal physiology · 2017
    Article
  7. Article
  8. Article
  9. Direct evidence of intracrine angiotensin II signaling in neurons.American journal of physiology. Cell physiology · 2014
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Intracardiac intracellular angiotensin system in diabetes.American journal of physiology. Regulatory, integrative and comparative physiology · 2012
    Review
  16. G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium.American journal of physiology. Cell physiology · 2011
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Elena DeliuDepartment of Pharmacology, Temple University School of Medicine, Philadelphia, Pennslyvania 19140, USA.
Andrei A Tica
Dana Motoc
G Cristina Brailoiu
Eugen Brailoiu
Temple University · USVasile Goldis Western University of Arad · RO

Funding

Role of nonnuclear estrogen receptor GPR30 in preganglionic vagal neuronsR01HL090804 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI BRAILOIU, EUGEN · 2009 to 2012
$1.5M
NHLBI NIH HHS R01 HL090804NHLBI NIH HHS R01HL-90804
6 · The paper itself

Abstract

Angiotensin II is a modulator of myometrial activity; both AT(1) and AT(2) receptors are expressed in myometrium. Since in other tissues angiotensin II has been reported to activate intracellular receptors, we assessed the effects of intracellular administration of angiotensin II via microinjection on myometrium, using calcium imaging. Intracellular injection of angiotensin II increased cytosolic Ca(2+) concentration ([Ca(2+)](i)) in myometrial cells in a dose-dependent manner. The effect was abolished by the AT(1) receptor antagonist losartan but not by the AT(2) receptor antagonist PD-123319. Disruption of the endo-lysosomal system, but not that of Golgi apparatus, prevented the angiotensin II-induced increase in [Ca(2+)](i). Blockade of AT(1) receptor internalization had no effect, whereas blockade of microautophagy abolished the increase in [Ca(2+)](i) produced by intracellular injection of angiotensin II; this indicates that microautophagy is a critical step in transporting the peptide into the endo-lysosomes lumenum. The response to angiotensin II was slightly reduced in Ca(2+)-free saline, indicating a major involvement of Ca(2+) release from internal stores. Blockade of inositol 1,4,5-trisphosphate (IP(3)) receptors with heparin and xestospongin C or inhibition of phospholipase C (PLC) with U-73122 abolished the response to angiotensin II, supporting the involvement of PLC-IP(3) pathway. Angiotensin II-induced increase in [Ca(2+)](i) was slightly reduced by antagonism of ryanodine receptors. Taken together, our results indicate for the first time that in myometrial cells, intracellular angiotensin II activates AT(1)-like receptors on lysosomes and activates PLC-IP(3)-dependent Ca(2+) release from endoplasmic reticulum; the response is further augmented by a Ca(2+)-induced Ca(2+) release mechanism via ryanodine receptors activation.

Indexed as

Angiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersAnimalsArsenicalsAutophagyBrefeldin ACalcium SignalingCarbolinesCells, CulturedEgtazic AcidEndocytosisEndoplasmic ReticulumEndosomesEnzyme InhibitorsEstrenes1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dioneAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersArsenicalsbafilomycin A1Brefeldin ACarbolinesEgtazic AcidEnzyme InhibitorsEstrenesHeparinImidazolesInositol 1,4,5-Trisphosphate ReceptorsLosartanMacrocyclic CompoundsMacrolidesNAADPNADPOxazolesoxophenylarsinePD 123319PiperazinesPyridinesPyrrolidinonesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2RyanodineSaralasinSirolimusType C Phospholipasesxestospongin C

Identifiers

PMID21613610
PMCPMC3174567
OpenAlexW1972152944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.